NCT06375733View on ClinicalTrials.gov

A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

March 20, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Large B-cell Lymphoma
Interventions
DRUG

GFH009

administered as an IV infusion at the dose levels 75mg, 60mg, and/or 100mg QW.

DRUG

Zanubrutinib

administered at 160mg BID oral; 28-day a cycle until disease progresses.

DRUG

GFH009

the RP2D of GFH009 defined in the preliminary phase 1b trial with the same schedule as in the phase Ib.

DRUG

Zanubrutinib

administered at 160mg BID oral; 28-day a cycle until disease progresses.

Trial Locations (2)

Unknown

RECRUITING

Guangxi Medical University Cancer Hospital&Guangxi Cancer Institute, Nanning

RECRUITING

Affiliated Cancer Hospital of Zhengzhou University Henan Cancer Hospital, Zhengzhou

All Listed Sponsors
lead

Genfleet Therapeutics (Shanghai) Inc.

INDUSTRY